Article Text

Download PDFPDF
Gynecological sarcomas, surgical management: primary, metastatic, and recurrent disease
  1. Gwenael Ferron1,2,
  2. Guillaume Bataillon3,
  3. Alejandra Martinez1,4,
  4. Frederic Chibon2,5 and
  5. Thibaud Valentin2,6
  1. 1 Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
  2. 2 OncoSARC (Oncogenesis of Sarcoma), INSERM UMR1037, Toulouse, France
  3. 3 Anatomopathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
  4. 4 T2i (Anti-tumour immunity and immunotherapy), INSERM UMR1037, Toulouse, France
  5. 5 Surgical Pathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
  6. 6 Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
  1. Correspondence to Dr Gwenael Ferron, Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, Languedoc-Roussillon-Midi 31059, France; ferron.gwenael{at}iuct-oncopole.fr

Abstract

Adult-type gynecological soft tissue and visceral sarcomas are rare tumors, with an estimated incidence of 13% of all sarcomas and 4% of all gynecological malignancies. They most often develop in the uterus (83%), followed by the ovaries (8%), vulva and vagina (5%), and other gynecological organs (2%). The objective of this review is to provide an overview of the current management of gynecological sarcomas, according to international guidelines. The management of gynecological sarcomas should follow the recommendations for the management of soft tissue and visceral sarcomas. Centralizing cases in expert centers improves patient survival, both for the diagnostic phase and for multidisciplinary therapeutic management. In the case of pelvic soft tissue sarcomas, a radiological biopsy is essential before any surgical decision is taken. In the case of a myometrial tumour which may correspond to a sarcoma, if conservative surgery such as myomectomy or morcellation is planned, an ultrasound-guided biopsy with pathological analysis including comparative genomic hybridization analysis must be carried out. In all cases, en bloc surgery, without rupture, is mandatory. Many rare histological subtypes require specific surgical management.

  • sarcoma
  • pelvis
  • pathology
  • surgical oncology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter @Alejandra

  • Contributors Conceptualization: GF, TV. Writing original draft: GF, TV, GB. Writing, reviewing, and editing: all the authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.